VolitionRx Expands Patent Portfolio with Ebola Triage Application Using Nu.Q Technology

VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company’s existing Nu.Q NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality. This expansion into infectious disease triage underscores the versatility of VolitionRx’s epigenetic platform and could address critical unmet needs during outbreaks.

According to the company, its CE-Marked automated Nu.Q NETs assay and recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions where laboratory infrastructure is limited. The ability to rapidly identify and isolate infected patients is crucial for controlling the spread of Ebola, which has a high fatality rate and often overwhelms healthcare systems in affected areas. VolitionRx is seeking partnerships with global health organizations, pharmaceutical developers, NGOs, and distribution partners to support field trials, manufacturing scale-up, and potential deployment in outbreak zones.

The implications of this announcement are significant. If successful, the Nu.Q-based test could enable earlier detection of Ebola, allowing for prompt treatment and containment measures. This would be a major advancement over current diagnostic methods, which often require sophisticated equipment and trained personnel. The lateral flow format, similar to a pregnancy test, is particularly promising for use in remote clinics and mobile health units. Moreover, the same technology could potentially be adapted for other infectious diseases, broadening its impact.

VolitionRx is a multi-national company focused on advancing the science of epigenetics, with research and development activities centered in Belgium, an innovation laboratory and office in the U.S., and an office in London. The company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. For more information, visit the company’s website at https://volition.com/.

The full press release can be viewed at https://ibn.fm/UOWP1. This development highlights VolitionRx’s commitment to expanding its patent portfolio and addressing global health challenges through innovative diagnostic solutions.